Papers/PMID:27215274
Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study.
BMC neurology2016The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
Andrographis paniculata — no detected effect on expanded Disability Status Scale (EDSS)
Evidence strength: moderate.FindingNull result“The EDSS score during the total period of treatment was similar for the A. paniculata and the placebo groups, and no significant differences were observed.”
Quoted verbatim from Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study.. - Study
- RCT
- Duration
- 12 months
- Dose
- one 170 mg tablet every 12 h
- Population
- Adults aged 18-50 with relapsing-remitting multiple sclerosis, all receiving interferon beta-1a
Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study.2016PMID:2721527410.1186/s12883-016-0595-2Permalink